A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
A 4-week Phase IIa study to evaluate the safety and tolerability and efficacy of NW-3509A in patients with chronic schizophrenia that are not responding adequately to their current antipsychotic medication (aripiprazole or risperidone). NW-3509A is given as an oral dose range of 15 to 25 mg, BID in a 1:1 ratio.
Epistemonikos ID: a4dc987f2945f08c8e4c391549b1ae7d757ce242
First added on: May 12, 2024